3-year follow-up of CheckMate 649: nivolumab + chemotherapy in GC/GEJC/EAC

CheckMate 649: nivolumab and chemotherapy or ipilimumab in GC/GEJC/EAC

CheckMate 649 biomarker analyses of NIVO + IPI vs chemo for patients with GC/GEJC/EAC

CheckMate 649: 1L nivo + chemotherapy improves OS

Biomarker analyses of the CheckMate 649 trial in GC/GEJC/EAC

Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study

Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020

2023 Updates in Clinical Oncology – Gastrointestinal and Recent Advances in Pediatric Neuro-oncology

29-month follow-up from CheckMate 648: nivolumab combination therapy in ESCC

Clinical Trials Updates for Gastric Cancer Patients Webinar

【JCF2023】胃がん

Nivolumab chemotherapy combination treatment: CheckMate649 and ATTRACTION-4

Overview of gastroesophageal cancer

September 26, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)

Adding Immunotherapy to First-Line Chemotherapy for Gastric Cancer: Data and Implications

CheckMate 459: Nivolumab plus chemotherapy for GC / GEJC / EAC

Expert Video Report on immunotherapy in gastro oesophageal cancer from 2021 ASCO Annual Meeting

What role will zolbetuximab play in treating gastric cancer?

Part 2 - Nivolumab with chemotherapy in advanced previously untreated Gastric - Dr. Anant Ramaswamy

Upper Gastrointestinal Cancer | 2022 OneOncology Conference